A case of hemorrhagic cystitis caused by nab-paclitaxel

Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044

Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC et al (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019–6026

Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30(17):2055–2062. doi: 10.1200/JCO.2011.39.5848

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. doi: 10.1056/NEJMoa1304369

Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P (2011) Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother 23(2):59–66

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803

Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E et al (2015) Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 33(21):2361–2369. doi: 10.1200/JCO.2014.59.5298

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356. doi: 10.1016/S1470-2045(15)00542-2

Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T (2010) Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol 40(5):404–411. doi: 10.1093/jjco/hyp192

Finley RS, Rowinsky EK (1994) Patient care issues: the management of paclitaxel-related toxicities. Ann Pharmacother 28(5 Suppl):S27–S30

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324

de Vries CR, Freiha FS (1990) Hemorrhagic cystitis: a review. J Urol 143(1):1–9

Stillwell TJ, Benson RC Jr, Burgert EO Jr (1988) Cyclophosphamide-induced hemorrhagic cystitis in Ewing’s sarcoma. J Clin Oncol 6(1):76–82

Payne H, Adamson A, Bahl A, Borwell J, Dodds D, Heath C et al (2013) Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int 112(7):885–897

Yanagi M, Nishimura T, Kurita S, Lee C, Kondo Y, Yamazaki K (2011) A case of prednisolone therapy for radiation-induced hemorrhagic cystitis. Nihon Hinyokika Gakkai Zasshi 102(3):600–602

Traxer O, Desgrandchamps F, Sebe P, Haab F, Le Duc A, Gattegno B et al (2001) Hemorrhagic cystitis: etiology and treatment. Prog Urol 11(4):591–601

Report of use-results survey for nab-pacitaxel conducted as all-case surveillance in Japan (2013). http://www.taiho.co.jp/index.html

MINK Web. Medical information by Nippon Kayaku. https://mink.nipponkayaku.co.jp/index2.html . 28 June 2016

Ntekim AI, Ajekigbe A (2010) Hemorrhagic cystitis in a patient receiving docetaxel for prostate cancer. Clin Med Insights Oncol 4:11–13

Grellety T, Houédé N, Hoepffner JL, Rivière J, Mérino C, Lieutenant V et al (2014) Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome? Ann Oncol 25(6):1248–1249. doi: 10.1093/annonc/mdu132

Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N et al (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14(13):4200–4205

Yardley DA (2013) nab-Paclitaxel mechanisms of action and delivery. J Control Release 170(3):365–372. doi: 10.1016/j.jconrel.2013.05.041